---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-028807"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:07:24.863474+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AVROBIO reports Q2 2022 net loss of $28.1M, cash runway into Q1 2024

## Summary
- Net loss of $28.1M in Q2 2022 vs $31.4M in Q2 2021; R&D expenses $18.9M, down from $22.5M.
- Cash and equivalents $132.4M as of June 30, 2022, down from $189.6M at Dec 31, 2021; runway into Q1 2024.
- All five patients in Phase 1/2 cystinosis trial remain off oral cysteamine post gene therapy.
- FDA Orphan Drug Designation granted for AVR-RD-05 in Hunter syndrome; CTA authorization expected 2H 2022.
- Plan to engage with regulators on cystinosis and Gaucher type 3 clinical strategies in 2H 2022.

## SEC filing metadata
- accession: 0001140361-22-028807
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000114036122028807/0001140361-22-028807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000114036122028807/brhc10040479_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-028807
- JSON: https://secwatch.observer/filing/0001140361-22-028807.json
- Plain text: https://secwatch.observer/filing/0001140361-22-028807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.